Chairman, Dr George Morstyn
Dr Morstyn has extensive experience in drug development and biotechnology. He was head of the clinical program at the Ludwig Institute for Cancer Research in Melbourne and Principal Investigator on the earliest clinical studies of haemopoietic growth factors. From 1991 to 2002, Dr Morstyn worked for Amgen, rising to Senior Vice President of Development and Chief Medical Officer in 1999. Dr Morstyn is Chair of the Board of GBS Bioventures and Board Member and Chair of the Scientific Advisory Board of Symbio (Japan). He is a member of the Commercialization Committee at the Walter and Eliza Hall Institute and has recently stepped down as Deputy Chair of the Victorian Comprehensive Cancer Centre (VCCC) and the Board of Therapeutic Innovation Australia.
Mrs Jane Bell
Jane Bell is a banking and finance lawyer and non-executive director with more than 30 years’ experience in leading law firms, financial services, corporate treasury operations and governance gained living in Melbourne, London, Toronto, San Francisco and Brisbane. Jane currently serves as a Director of UCA Funds Management Limited, Royal Melbourne Hospital (Melbourne Health), Chair of the Advisory Committee of the Melbourne Genomics Health Alliance and member of the Audit Committee of The Salvation Army. Jane is a former Board member of WorkSafe Victoria, Australian Red Cross (Qld), Monash Institute of Medical Research-Prince Henry’s Institute of Medical Research, Queensland Institute of Medical Research, Victorian Women’s Housing Association and Deputy Chair of Westernport Water Corporation. Jane holds a Bachelor of Laws from the University of Melbourne, Bachelor of Economics from Monash University and a Master of Laws from Kings College, London and is a Fellow of the Australian Institute of Company Directors.
Dr Anna Lavelle
Dr Anna Lavelle is an experienced non–executive director serving for over 25 years on the boards of not for profit, government and for profit entities. As executive director or non-executive director she has been continuously developing strong governance skills and in particular has a lengthy track record in healthcare delivery, technology development and government policy. Anna has an intimate understanding of the biotechnology, medical technology and pharmaceutical ecosystems and the related stakeholder groups. Anna has a BSc (Hons), PhD in Genetics from The University of Melbourne and is a Graduate of the Australian Institute of Company Directors (AICD). A Fellow of the Australian Academy of Technological Sciences and Engineering, Anna is also a Fellow of the Leadership Victoria program and a Graduate of “Mastering the Boardroom”, the AICD Advanced Governance Program. In 2015 Scientific American World View ranked Anna in the global top 100 “World Visionaries” in biotechnology, the only Australian to be listed. In 2010 Anna was awarded the National Australia Bank “Yachad Scholarship”. Dr Lavelle’s most recent executive position was as CEO of AusBiotech, the national industry association for the biotechnology and medical devices sector. Whilst CEO, Anna successfully negotiated legislative changes that better supported the innovation sector. She is the Deputy Chair of Medicines Australia in addition holding board positions on several for profit technology companies.
Professor Matthew Gillespie
Professor Gillespie is Associate Dean (Research Strategy), Faculty of Medicine, Nursing and Health Sciences at Monash University. Matthew trained in microbiology and immunology, and is a bone cell biologist and cancer researcher. He was director of Prince Henry’s Institute 2008-2013, he has held high-level research administration roles in other leading research organisations, including as Associate Director of Melbourne’s St Vincent’s Institute of Medical Research. An active member of the Australian and global scientific communities, Professor Gillespie has held editorial roles including on the boards of Arthritis and Rheumatism, Endocrinology, Bone, and the Journal of Bone and Mineral Research and on research committees including the Cancer Council Victoria, NHMRC Research Committee and NHMRC Audit Committee (current). He was president of the Australian Society for Medical Research (1999-2000) and the Australian and New Zealand Bone and Mineral Society (2011-2013).
Professor Michael Parker
Professor Michael Parker is Director of the Bio21 Institute, University of Melbourne and Head of Structural Biology, St. Vincent’s Institute of Medical Research in Melbourne. He is an NHMRC Senior Principal Research Fellow. After obtaining his D. Phil. in protein crystallography from Oxford University, Michael returned to Australia to re-establish a protein crystallography laboratory at St. Vincent’s in 1991. The work of the laboratory is internationally recognised with the determination of more than 140 crystal structures of proteins involved in cancer, Alzheimer’s disease and infection. He has published over 300 papers and his work has been recognised with numerous awards including the 1999 Gottschalk Medal of the Australian Academy of Science, a 2006 Federation Fellowship from the Australian Research Council, the 2011 Lemberg Medal of the Australian Society for Biochemistry and Molecular Biology, the 2011 Ramaciotti Medal for Excellence in Biomedical Research and the 2012 Federation of Asian and Oceanian Biochemists and Molecular Biologists Award for Research Excellence. He was elected a Fellow of the Australian Academy of Science in 2010 and a Fellow of the Australian Academy of Health and Medical Sciences in 2015. He is currently Chair of the National Committee of Crystallography under the auspices of the Australian Academy of Science.
Dr Megan Robertson
Professor Stephen Holdsworth
Professor Holdsworth is a clinical academic with specialty training in nephrology and immunology and a research focus on autoimmune kidney diseases. Prof Holdsworth established the Centre for Inflammatory Diseases in the Department of Medicine at Monash Health comprising a group of 70 researchers focusing on the inflammatory mediation of human autoimmune diseases including vasculitis, arthritis and SLE. He has served on NHMRC Research Committee and has been Chair of the NHMRC Program Grant Committee. He has served as Head of the Southern Clinical School and Head of the Department of Medicine and as Associate Dean Research for the Faculty of Medicine. Prof Holdsworth is currently Head of Clinical and Diagnostic Immunology at Monash Health and Head of the Renal Autoimmunity Division in the Centre for Inflammatory Diseases.
Keith McLean has a BSc and PhD from the University of Aberdeen, Scotland. Following work in industry he undertook postdoctoral research in Scotland and New Zealand before joining the Commonwealth Scientific and Industrial Research Organisation (CSIRO) working on surface modification and characterisation for ophthalmic and other polymeric biomaterials applications. He was Research Director for Biomedical Materials and Devices from 2006-2014 leading a multi-disciplinary team of materials scientists and biologists developing biomaterials and implantable devices. He won the 2004 Royal Societies of Australia Eureka Award for Interdisciplinary Research and the 2009 CSIRO Medal for Research Achievement. He became Director of CSIRO Manufacturing in 2014 leading >400 scientists working in chemical, biomedical and advanced manufacturing. McLean also sits on the Board of CRC Polymers; HySSIL Pty Ltd; and veski. Dr McLean is an Adjunct Professor at Monash University and was recently appointed as a Fellow Biomaterials Science and Engineering (FBSE).
Professor Jeffrey Zajac
Professor Zajac is Professor and Head of The University of Melbourne, Department of Medicine at Austin Health. He is a Clinical Endocrinologist and General Physician with research interests in molecular endocrinology. He is Chairman of Medicine and Director of the Department of Endocrinology at Austin Health. After gaining his PhD in the Department of Medicine, Austin & Repatriation Medical Centre and postdoctoral work in the Endocrine Genetics Unit at Massachusetts General Hospital, Boston, he returned to The University of Melbourne initially at Royal Melbourne Hospital and now Austin Health. His research group has embarked on a major research program investigating the effect of androgen deprivation therapy in patients with prostate cancer. These investigations include effects on bone, muscle, cardiovascular risk and metabolic state. Prof Zajac also heads a molecular endocrinology group investigating the androgen receptor using genetically modified mice.
Professor David Thorburn
David Thorburn leads the Genetics Research Theme and Mitochondrial Research Group at Murdoch Childrens Research Institute. He is an Honorary Professorial Fellow in the University of Melbourne Department of Paediatrics and an NHMRC Principal Research Fellow. David received his PhD from the University of Sydney in 1987 before completing Fulbright and NHMRC C.J. Martin Fellowships at Scripps Clinic, La Jolla, California. He returned to Australia in 1990 to what was then called the Murdoch Institute. He is a Fellow, and former President, of the Human Genetics Society of Australasia. He is also a Fellow, and Principal Examiner in Genetics, of the Faculty of Science of the Royal College of Pathologists of Australasia.